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Objective: Misoprostol can be used by different routes in the medical management of abortion. This 
study aimed to compare the efficacy and safety of buccal and vaginal administration of misoprostol 
for the completion of first-trimester abortions. 
Materials and Methods: This study was a randomized clinical trial in which women with first-
trimester abortion referred to Imam Hossein Medical Center in 2018 were studied. Women were 
randomly divided into two groups of buccal or vaginal misoprostol treatment. From the time of drug 
administration to complete abortion, side effects, duration of drug use until tissue excretion, need for 
blood transfusion and need for surgical evacuation were recorded and compared in two groups. 
Results: One-hundred women (each group, 50 patients) were evaluated in this study. There was a 
significant difference between the two groups regarding the duration of misoprostol use (p-value = 
0.028), and it was longer in the buccal group. Besides, there was a significant difference between the 
two groups in terms of the dose required until the tissue discharge (p-value = 0.034). In the buccal 
group, patients received higher doses of misoprostol. The rate of fever had a significant difference 
between the two groups and was more frequent in the vaginal group (p-value=0.023). 
Conclusion: Vaginal misoprostol can be more effective in treating first-trimester abortions compared 
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Introduction 
Abortion is considered a spontaneous fetal loss 
before the age of fetal viability (1). Women 
diagnosed with first-trimester abortion with 
the ultrasonography, can be managed 
expectantly, medically, or surgically (2). 
Traditionally, uterine evacuation by aspiration 
curettage was known as the gold-standard 
technique for the treatment of spontaneous 
abortion (3). However, medical management 
with misoprostol is an alternative to surgery 
for managing first-trimester abortions and is 
now regarded as being the primary choice for 
the management of early gestational loss in 
many centers (4, 5). The treatment of first-
trimester abortions with misoprostol has many 
advantages over surgical treatment. It can be 
done in an outpatient setting, and 
hospitalization is not required. So, it appears to 
be more cost-effective management (6). 
Misoprostol is a prostaglandin E1 analogue, 
which is effective, inexpensive, and requires 
no needles for administration. In addition, it 
has fewer side effects than prostaglandin E2 
analogues (7, 8). 
Misoprostol can be used both by oral and 
vaginal routes; however, some clinical studies 
in the medical management of abortion found 
that the vaginal route might be more effective 
than oral administration because the oral route 
has extensive and rapid first-pass metabolism 
(9). Fewer drug doses administered vaginally 
can slowly induce contraction of the uterus 
and maintain it for labor induction. Because of 
the higher peak in oral administration, the side 
effects are more than the vaginal route (10). 
However, vaginal administration requires 
frequent vaginal examinations, which are 
inconvenient and may not be acceptable for 
many patients despite its effectiveness (11). 
Other routes of misoprostol administration, 
such as buccal and sublingual, have also been 
tried (12, 13). The buccal route (between the 
gums and cheek) has easier administration and 
lesser infection rates compared to the vaginal 
route (14). 
This study aimed to compare the efficacy and 
safety of buccal and vaginal administration of 
misoprostol for the completion of first-
trimester abortions. 
 
Materials and Methods 
This study was a randomized clinical trial in 
which women with first-trimester abortion 
referred to Imam Hossein Medical Center 
affiliated to Shahid Beheshti University of 
Medical Sciences, Tehran, Iran, in 2018 were 
studied. The study protocol was approved by 
the ethics committee of Shahid Beheshti 
University of Medical Sciences and was done 
following the principles of the declaration of 
Helsinki. Informed consent was obtained from 
all women to participate in the study. Inclusion 
criteria were ≥18 years of age, gestational age 
between 6 weeks to 13 weeks and 6 days and 
exclusion criteria were cardiovascular or 
cerebrovascular diseases, severe anemia, 
hypertension, Severe hepatitis, severe kidney 
disease, chronic adrenal insufficiency, severe 
asthma requiring systemic steroids, 
inflammatory bowel disease, evidence of 
cervical infection, any allergies and 
contraindications to the use of misoprostol or 
women who for any reason were unwilling to 
participate in the study.  
Age, parity, gravidity, and gestational age of 
all women were recorded, and they subjected 
to a general and an obstetric examination. In 
addition, a baseline hemoglobin level of all 
patients was measured, and transvaginal 
ultrasonography was done to confirm the 
diagnosis of abortion. 
After confirmation of abortion, the women 
were randomly divided into two groups of 
buccal or vaginal misoprostol treatment. The 
treatment compromised 800 µg misoprostol in 
the vaginal group and 600 µg in the buccal 
group, up to two doses every three hours. All 
doses were administered under the supervision 
of obstetrics and gynecology residents at the 
hospital. 
From the time of drug administration to 
complete abortion, side effects (including 
fever, nausea and vomiting, diarrhea, bleeding, 
and need for blood transfusion) and duration 
of drug use until tissue excretion and need for 
Surgical evacuation were recorded and 
compared in two groups. The physician who 
recorded the final outcomes was blinded to the 
group of patients. 
 
Statistical Analysis 
Quantitative variables with normal and 
abnormal distribution were presented as mean 
± standard deviation and median (interquartile 
range), respectively.  Frequency (%) was used 
to represent qualitative variables. Qualitative 
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test, and quantitative variables with normal 
distribution were analysed using Student's t-
test. Quantitative variables with abnormal 
distribution were also analysed by the Mann-
Whitney test. The normal distribution of 
variables was evaluated by the Shapiro-Wilk 
test. The p-value = 0.05 was significant in all 
analyses. All analyses were performed by 
SPSS software SPSS 21.  
 
Results 
One-hundred women (each group, 50 patients) 
evaluated in this study. The distribution of age, 
body mass index and gestational age for these 
two groups are reported in Table 1. In 
addition, the parity was similar in the two 
groups, and the median (interquartile range) 
was 2 (1-3) in both groups, and there was no 
significant difference between the two groups 
(p-value = 0.226). There was no significant 
difference between the two groups in each 
variable and they were matching similar with 
respect to demographic profile and obstetrical 
parameters. 
 
The duration of misoprostol administration 
until the tissue discharge (Induction–expulsion 
interval) is shown in table 2. There was a 
significant difference between the two groups 
regarding the duration of misoprostol use (p-
value = 0.028), and it was longer in the buccal 
group. The rate of surgical evacuation required 
in the two groups is also shown in Table 2. 
There was no significant difference between 
the two groups in this regard (p-value = 
0.461). In addition, as the required doses of 
misoprostol in the two groups are shown in 
Table 2, there was a significant difference 
between the two groups in terms of the dose 
required until the tissue discharge (p-value = 
0.034). In the buccal group, patients received 
higher doses of misoprostol. 
 
 
The rate of different possible side effects of 
misoprostol use is shown in table 3. Among 
these variables, only the rate of fever had a 
significant difference between the two groups 





There is ample evidence that misoprostol is a 
safe, effective, and acceptable method of 
uterine drainage for women requiring post-
abortion care. Misoprostol reduces the cost of 
post-abortion care services because it does not 
require immediate access to sterile settings, 
operating rooms, or skilled personnel (15). It is 
inexpensive, does not require a refrigerator, 
and can be administered by several different 
routes (16). 
In this study, the effects of buccal and vaginal 
misoprostol on first-trimester abortions were 
investigated and showed that the amount of 
bleeding, need for surgical evacuation, 
hemoglobin level changes, need for blood 
transfusion, nausea, vomiting, and diarrhea did 
not significantly differ after using buccal or 
vaginal misoprostol. However, the induction–
expulsion interval was significantly longer in 
the buccal group. Also, the required dose was 
significantly higher in the buccal group. 
However, fever was significantly more 
frequent in patients of the vaginal group. 
The study by Khan et al. showed efficacy 
(complete abortion) of 88% in the vaginal 
group and 94% in the buccal group in first-
trimester abortions. This difference was not 
statistically significant (P-value >0.05) (12). 
Middleton et al. also reported the 95% efficacy 
of 800 µg mifepristone in the buccal group and 
93% in the vaginal group (P-value=0.51) (17). 
Geetika Garg et al., in a randomized controlled 
trial, reported that the success rate in the 
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group was 88% (P-value >0.05) (18). Fjerstad 
et al. reported a 98.3% success rate in medical 
abortion with 200 mg mifepristone plus 200 µg 
of buccal misoprostol over 24 to 48 hours  (P-
value >0.05) (19). 
Our results showed that the induction–
expulsion interval and dose of drug required 
for tissue discharge were significantly higher 
in the buccal group than in the vaginal group 
and might indicate a higher efficacy of vaginal 
misoprostol. However, these studies that 
showed no significant difference in efficacy of 
vaginal and buccal misoprostol evaluated the 
first-trimester induced abortions. 
Wiebe et al. used misoprostol 600 µg by 
buccal or vaginal routes 3 to 6 days after 50 
mg/m2 methotrexate and reported that 
complete abortion on day 8 was 14% greater in 
the vaginal group and that vaginal misoprostol 
is more effective than the buccal, which can be 
similar to the results of our study. In their 
study, the vaginal route was more acceptable 
than buccal for patients, which may be due to 
the burning sensation and the need to keep 
tablets in the mouth. 
The controversial point of many published 
clinical trials on the treatment of premature 
abortion is the definition of success rate. Some 
studies have used the endometrial thickness of 
15 mm assessed by transvaginal ultrasound as 
a cut-off for complete abortion (15). However, 
evidence from studies of medical termination 
of missed abortions indicates that this value is 
too stringent (20, 21). Studies that usually 
report success rates above 95% do not use 
endometrial thickness to define the success 
rate (22). 
Unusual differences in success rates in 
different studies may be due to various factors 
such as patient selection, concomitant use of 
mifepristone, and differences in dose, route, 
and time interval of misoprostol 
administration. While some studies included 
patients with incomplete abortion, others 
included missed abortions or a combination of 
both (7, 23). 
There was no significant difference in vaginal 
bleeding between the two groups, with most 
patients reporting amount similar to menses.  
There was no significant difference in 
hemoglobin level changes between the two 
groups. Also, there was no significant 
difference in blood transfusion between the 
two groups, and only one patient in the vaginal 
group needed a blood transfusion. In our 
study, except for the fever, there were no 
statistically significant differences in drug-
related side effects similar to those of 
Middleton et al. (17), Geetika Garg et al. (18), 
and Khan et al. (12). The incidence of fever 
was significantly higher in the vaginal group 
patients. Also, the nausea rate following 
misoprostol use in the vaginal group was 20%, 
and in the buccal group was 16%. Vomiting 
rate was 10% in the vaginal group and 4% in 
the buccal group. In the study of Khan et al. 
(12), nausea was 14% in buccal, and 10% in 
vaginal groups and taste change (12%) was an 
additional negative side effect in the buccal 
route. They also reported a satisfaction rate of 
90% in the vaginal group and 94% in the 
buccal group.  
The main strengths of our study were that it 
was randomized and included a relatively large 
sample size in which the effect of buccal 
misoprostol was compared with the vaginal 
route. Also, all patients were given 
misoprostol under obstetrics and gynecology 
resident instruction in a timely manner. 
However, this study also has some limitations. 
We did not evaluate patient satisfaction 
because participants could not be blinded to 
the route of treatment, and the outcome of 
treatment might affect their preference and 
satisfaction with a particular route. The 
success rate in our study was also measured by 
the duration of misoprostol use and the dose 
required to discharge tissue, while many other 
studies have considered the success rate as 
complete abortion without required surgical 
intervention. Vaginal misoprostol can be more 
effective in treating first-trimester abortions 
compared to buccal misoprostol and may be 
associated with longer duration of use and 
lower required doses. Further clinical trials 
with larger sample sizes are recommended to 
confirm the results of our study. 
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